Eversana has announced a collaboration with ChemoMouthpiece to support the US launch and commercialisation of the latter’s medical device for oncology patients.
The Chemo Mouthpiece device is an intraoral ice pack that helps patients with cancer manage and treat oral mucositis, a painful side effect of chemotherapy.
The device has been designed to deliver cryotherapy to the oral cavity of patients receiving chemotherapy.
Recently, the Chemo Mouthpiece secured Breakthrough Device Designation from the US Food and Drug Administration (FDA) to reduce the incidence and severity of oral mucositis.
It will also allow patients to continue their treatment with minimal discomfort.
According to the partnership terms, Eversana will be responsible for offering a complete range of commercialisation services to support the US launch of the device.
These services will include, but are not limited to, market access strategy, patient services, compliance and regulatory services, field deployment solutions, pricing strategy, data and analytics, and 3PL distribution services.
Eversana CEO Jim Lang said: “The innovative team at ChemoMouthpiece is dedicated to what matters most in our industry – improving the lives of patients.
“Their patented technology provides a significant advancement in improving the quality of life during chemotherapy treatment.”
The Chemo Mouthpiece device works by cooling the complete oral cavity.
By freezing the device at home, patients can carry it with them for use at the time of treatment.
ChemoMouthpiece inventor, founder and CEO David Yoskowitz said: “Commercialising medical devices, especially for oncology, is extremely complex, and as we continue to work to bring the Chemo Mouthpiece to market we need a partner that has experience not only in commercialisation but with intricate knowledge of the oncology space.”
Pending regulatory approvals, the device is slated for a US launch later in the year.